ArticleBipolar disorders2026
Trends in the Use of Atypical Antipsychotics Among Children and Adolescents With Bipolar Spectrum Disorders in Korea.
Article in Bipolar disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionAtypical antipsychotics (AAPs) are increasingly prescribed for bipolar spectrum disorders in children and adolescents. This study aimed to investigate the prevalence and trends of AAP prescriptions among Korean children and adolescents with bipolar spectrum disorders.
methodsWe analyzed data from the Korean National Health Insurance Review and Assessment Service to assess AAP use among Koreans aged 0-18 years with bipolar spectrum disorders between 2010 and 2022. This population-based study used an annual cross-sectional assessment to evaluate trends in AAP prescription.
resultsThe prevalence of AAP prescriptions for children and adolescents with bipolar spectrum disorders increased over the 13-year study period, rising from 0.14 in 2010 up to 1.23 per 1000 persons in 2022. During this time, the dominant AAP shifted from risperidone to aripiprazole. Data from 2022 revealed that the most prescribed AAP for children was aripiprazole, followed by risperidone, quetiapine, and olanzapine. Children and adolescents with bipolar spectrum disorders and psychiatric comorbidities, particularly ADHD, were prescribed AAPs more frequently (p < 0.001).
conclusionThe prescription of AAPs in Korean children and adolescents with bipolar spectrum disorders has increased over the last decade. This trend was particularly pronounced among individuals with psychiatric comorbidities, especially ADHD. Future research is needed to develop more evidence-based AAP treatments for bipolar spectrum disorders in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.